Prostate cancer is the most commonly diagnosed, noncutaneous cancer and the second leading cause of cancer-related deaths of men in North America. When diagnosed at an early stage, prostate cancer is frequently curable by surgery or radiation. However, if progression and metastases develop, the disease becomes increasingly difficult to treat; and 27,540 men are expected to die of the disease in North America in 2016. The approved regimens for recurrent metastatic castration resistant prostate cancer (mCRPC) including androgen receptor (AR) inhibitors, chemotherapy, radiation and immunotherapy only extend life by months and are thus not curative treatment options. Clearly, effective new treatments are urgently required in order to save the lives of men with mCRPC.